PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1...

Full description

Bibliographic Details
Main Authors: Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran Bueno, Reyes Bernabé-Caro, Diego Pérez Parente, Pedro Ruiz-Gracia, Marta Marina Arroyo, Luis Paz-Ares
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
non-small cell lung cancer
network meta-analysis
immunotherapy
first-line treatment
PD-(L)1 inhibitors
efficacy
Online Access:https://www.mdpi.com/2077-0383/10/7/1365

Internet

https://www.mdpi.com/2077-0383/10/7/1365

Similar Items